Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.

Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
复制标题

DOI:
10.1002/gcc.20563
复制
发表时间:
2008-07
影响因子:
3.7
通讯作者:
Kuehl, W. Michael
Kuehl, W. Michael
中科院分区:
医学2区
文献类型:
--
作者:
Gabrea, Ana;Martelli, Maria Luisa;Qi, Ying;Roschke, Anna;Barlogie, Bart;Shaughnessy, John D., Jr.;Sawyer, Jeffrey R.;Kuehl, W. Michael

文献摘要

参考文献

被引文献

相似文献

The pathogenesis of multiple myeloma (MM) is thought to involve at least two pathways, which generate hyperdiploid (HRD) or nonhyperdiploid (NHRD) tumors, respectively. Apart from chromosome content, the two pathways are distinguished by five primary immunoglobulin heavy chain (IGH) rearrangements (4p16, FGFR3, and MMSET; 6p21, CCND3; 11q13, CCND1; 16q23, MAF; 20q12, MAFB) that are present mainly in NHRD tumors. To determine the prevalence and structures of IGH, immunoglobulin (IG) light chain, and MYC genomic rearrangements in MM, we have done comprehensive metaphase fluorescent in situ hybridization analyses on 48 advanced MM tumors and 47 MM cell lines. As expected, the prevalence of the five primary IGH rearrangements was nearly 70% in NHRD tumors, but only 12% in HRD tumors. However, IGH rearrangements not involving one of the five primary partners, and IG light chain rearrangements, have a similar prevalence in HRD and NHRD tumors. In addition, MYC rearrangements, which are thought to be late progression events that sometimes do not involve an IG heavy or light chain locus, also have a similar prevalence in HRD and NHRD tumors. In contrast to the primary IGH rearrangements, which usually are simple balanced translocations, these other IG rearrangements usually have complex structures, as previously described for MYC rearrangements in MM. We conclude that IG light chain and MYC rearrangements, as well as secondary IGH rearrangements, make similar contributions to the progression of both HRD and NHRD MM tumors.†
DOI: 10.1182/blood.v99.6.2185
发表时间: 2002-03-15
期刊: BLOOD
影响因子: 20.3
作者:
Avet-Loiseau, H;Facon, T;Bataille, R
通讯作者: Bataille, R
DOI: 10.1182/blood-2003-02-0493
发表时间: 2003-10-01
期刊: BLOOD
影响因子: 20.3
作者:
Fonseca, R;Debes-Marun, CS;Greipp, PR
通讯作者: Greipp, PR
DOI: 10.1038/sj.onc.1204641
发表时间: 2001-09-10
期刊: ONCOGENE
影响因子: 8
作者:
Bergsagel, PL;Kuehl, WM
通讯作者: Kuehl, WM
DOI: 10.1182/blood.v98.7.2229
发表时间: 2001-10-01
期刊: BLOOD
影响因子: 20.3
作者:
Smadja, NV;Bastard, C;Fruchart, C
通讯作者: Fruchart, C
DOI: 10.1182/blood-2005-01-0034
发表时间: 2005-07-01
期刊: BLOOD
影响因子: 20.3
作者:
Bergsagel, PL;Kuehl, WM;Shaughnessy, J
通讯作者: Shaughnessy, J